BINEX Co. Ltd (053030) - Total Liabilities

Latest as of September 2025: ₩117.14 Billion KRW ≈ $79.38 Million USD

Based on the latest financial reports, BINEX Co. Ltd (053030) has total liabilities worth ₩117.14 Billion KRW (≈ $79.38 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

BINEX Co. Ltd - Total Liabilities Trend (2004–2024)

This chart illustrates how BINEX Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is BINEX Co. Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.

BINEX Co. Ltd Competitors by Total Liabilities

The table below lists competitors of BINEX Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Sparebank 1 Nordvest
OL:SNOR
Norway Nkr25.68 Billion
Shanghai Highly Group Co Ltd B
SHG:900910
China $15.67 Billion
Sangsin Energy Display Precision Co.Ltd
KQ:091580
Korea ₩191.48 Billion
Net Lease Office Properties
NYSE:NLOP
USA $84.00 Million
E-Data Teknoloji Pazarlama AS
IS:EDATA
Turkey TL374.63 Million
Toya SA
WAR:TOA
Poland zł173.66 Million
Kangda International Environmental Company Limited
STU:27K
Germany €12.37 Billion
Atlantic Lithium Ltd
AU:A11
Australia AU$3.35 Million

Liability Composition Analysis (2004–2024)

This chart breaks down BINEX Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of BINEX Co. Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.62 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.63 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BINEX Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BINEX Co. Ltd (2004–2024)

The table below shows the annual total liabilities of BINEX Co. Ltd from 2004 to 2024.

Year Total Liabilities Change
2024-12-31 ₩97.78 Billion
≈ $66.26 Million
+29.19%
2023-12-31 ₩75.69 Billion
≈ $51.29 Million
-29.14%
2022-12-31 ₩106.80 Billion
≈ $72.38 Million
+16.00%
2021-12-31 ₩92.07 Billion
≈ $62.39 Million
-4.96%
2020-12-31 ₩96.88 Billion
≈ $65.65 Million
+129.10%
2019-12-31 ₩42.29 Billion
≈ $28.66 Million
+3.17%
2018-12-31 ₩40.99 Billion
≈ $27.78 Million
+5.04%
2017-12-31 ₩39.02 Billion
≈ $26.44 Million
+6.76%
2016-12-31 ₩36.55 Billion
≈ $24.77 Million
+14.32%
2015-12-31 ₩31.97 Billion
≈ $21.67 Million
+28.80%
2013-12-31 ₩24.82 Billion
≈ $16.82 Million
-52.18%
2012-12-31 ₩51.90 Billion
≈ $35.17 Million
+72.44%
2011-12-31 ₩30.10 Billion
≈ $20.40 Million
+105.73%
2007-12-31 ₩14.63 Billion
≈ $9.91 Million
+1.63%
2006-12-31 ₩14.40 Billion
≈ $9.76 Million
+6.15%
2005-12-31 ₩13.56 Billion
≈ $9.19 Million
-26.46%
2004-12-31 ₩18.44 Billion
≈ $12.50 Million
--

About BINEX Co. Ltd

KQ:053030 Korea Pharmaceuticals
Market Cap
$173.31 Million
₩255.74 Billion KRW
Market Cap Rank
#17227 Global
#694 in Korea
Share Price
₩8200.00
Change (1 day)
+3.27%
52-Week Range
₩7500.00 - ₩18490.00
All Time High
₩36100.00
About

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; … Read more